Key result
Recurrent thrombotic events occur in approximately 10% of patients in the first year following an acute coronary syndrome event despite treatment with potent P2Y12 inhibitors.
Why the study?
Questions remain regarding optimal long-term antithrombotic therapy for chronic vascular disease, given recurrent thrombotic events in approximately 1 in 10 patients within the first year after an ACS event despite potent P2Y 12 inhibitors.
Does combination antiplatelet and oral anticoagulant therapy improve outcomes in patients with coronary and peripheral artery disease?
Does combination antiplatelet and oral anticoagulant therapy improve outcomes in patients with coronary and peripheral artery disease?
This review summarizes the rationale and clinical evidence for combining antiplatelet and oral anticoagulant therapy to reduce recurrent thrombotic events in patients with coronary and peripheral artery disease.
No takes yet. Share an insight, caveat, or question.
Residual ischemic risk after ACS on potent P2Y12 inhibition supports trials of combination regimens; leaves open net clinical benefit versus bleeding.
Gurbel et al. (2019) conducted a review in Coronary and peripheral artery disease. Combination antiplatelet and oral anticoagulant therapy was evaluated. Recurrent thrombotic events occur in approximately 10% of patients in the first year following an acute coronary syndrome event despite treatment with potent P2Y12 inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: